Sepracor Isomer of J&J Propulsid Could Expand Indications

Janssen will fund investigation of Sepracor's norcisapride, a single-isomer version of the Johnson & Johnson subsidiary's Propulsid (cisapride), for bulimia, emesis and irritable bowel syndrome, as well as for Propulsid's current indication in gastroesophogeal reflux disease, Sepracor CEO Timothy Barberich reported in a July 21 conference call.